Results 301 to 310 of about 28,689 (318)

High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib

Leukemia, 2021
Tiziano Barbui, Alessandro Maria Vannucchi, Alberto Alvarez-Larran   +2 more
exaly  

The potential of JAK/STAT pathway inhibition by ruxolitinib in the treatment of COVID-19

Cytokine and Growth Factor Reviews, 2020
Bakiye Goker Bagca, Cigir Biray Avci
exaly  

Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey

Leukemia, 2015
Robert Zeiser, Claudia Lengerke, Il-Kang Na   +2 more
exaly  

Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease

New England Journal of Medicine, 2020
Robert Zeiser, Nikolas von Bubnoff, Jason Butler   +2 more
exaly  

Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study

Lancet Oncology, The, 2017
Francesco Passamonti, Martin Griesshammer, Francesca Palandri   +2 more
exaly  

Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study

Lancet Haematology,the, 2017
Claire N Harrison, Nicolaas P M Schaap, Alessandro Maria Vannucchi   +2 more
exaly  

Treatment of atopic dermatitis with ruxolitinib cream (JAK1/JAK2 inhibitor) or triamcinolone cream

Journal of Allergy and Clinical Immunology, 2020
Michael D Howell
exaly  

Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis

Cancer, 2020
Francesca Palandri, Massimo Breccia, Massimiliano Bonifacio   +2 more
exaly  

Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial

Lancet Haematology,the, 2019
Moshe Talpaz, Philip S Boonstra, Ryan A Wilcox   +2 more
exaly  

Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study

Lancet Haematology,the, 2020
Jean-Jacques Kiladjian, Pierre B Zachée, Tamas Masszi   +2 more
exaly